Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Advances in the genetics of nonalcoholic fatty liver disease
Veeral Ajmera, Rohit Loomba
Current Opinion in Gastroenterology (2023) Vol. 39, Iss. 3, pp. 150-155
Open Access | Times Cited: 22

Showing 22 citing articles:

The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Luis Antonio Díaz, Juan Pablo Arab, Alexandre Louvet, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 764-783
Closed Access | Times Cited: 90
Pharmacologic inhibition of lipogenesis for the treatment of NAFLD
William P. Esler, David E. Cohen
Journal of Hepatology (2023) Vol. 80, Iss. 2, pp. 362-377
Open Access | Times Cited: 40
Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment
Norbert Stefan, Hannele Yki‐Järvinen, Brent A. Neuschwander‐Tetri
The Lancet Diabetes & Endocrinology (2024)
Open Access | Times Cited: 16
Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications
Ewelina Młynarska, Witold Czarnik, Natasza Dzieża, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1094-1094
Open Access | Times Cited: 2
New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice
Clémence M. Canivet, Jérôme Boursier, Rohit Loomba
Seminars in Liver Disease (2024) Vol. 44, Iss. 01, pp. 035-042
Closed Access | Times Cited: 8
Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants
Fernando Bril, Srilaxmi Kalavalapalli, Romina Lomonaco, et al.
JHEP Reports (2024) Vol. 6, Iss. 7, pp. 101092-101092
Open Access | Times Cited: 8
Effect of Intermittent Fasting on Lipid Profile, Anthropometric and Hepatic Markers in Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review
María Fernanda Castillo, Daniela Salgado-Canales, Marco Arrese, et al.
Current Vascular Pharmacology (2024) Vol. 22, Iss. 3, pp. 187-202
Closed Access | Times Cited: 4
Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population
Elias B. Rashu, Mikkel Werge, Liv Eline Hetland, et al.
Clinics and Research in Hepatology and Gastroenterology (2024) Vol. 48, Iss. 7, pp. 102389-102389
Closed Access | Times Cited: 4
NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review
Consolato Sergi
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8462-8462
Open Access | Times Cited: 4
Unraveling Mechanisms of Genetic Risks in Metabolic Dysfunction–Associated Steatotic Liver Diseases: A Pathway to Precision Medicine
Xiang Zhang, Kyong‐Mi Chang, Jun Yu, et al.
Annual Review of Pathology Mechanisms of Disease (2025) Vol. 20, Iss. 1, pp. 375-403
Closed Access
Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitis
Ikki Sakuma, Rafael Calais Gaspar, Ali Nasiri, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Evolutionäre Aspekte der mit metabolischer Dysfunktion assoziierten steatotischen Lebererkrankung (MASLD)
Andreas Geier, Stephan Schiffels, Marcin Krawczyk
Deleted Journal (2025)
Closed Access
The effect of calcium and vitamin A in patients with metabolic-associated fatty liver diseases
Reem M. Makbol, Zeinab Mahmoud kadry, Mohamed Mamdouh Noaman, et al.
Beni-Suef University Journal of Basic and Applied Sciences (2025) Vol. 14, Iss. 1
Open Access
Updated recommendations for the management of metabolic dysfunction–associated steatotic liver disease (MASLD) by the Latin American working group.
Luis Antonio Díaz, Juan Pablo Arab, Francisco Idalsoaga, et al.
Annals of Hepatology (2025), pp. 101903-101903
Open Access
The mitochondrial amidoxime reducing component—from prodrug-activation mechanism to drug-metabolizing enzyme and onward to drug target
Michel A. Struwe, Axel J. Scheidig, Bernd Clement
Journal of Biological Chemistry (2023) Vol. 299, Iss. 11, pp. 105306-105306
Open Access | Times Cited: 8
MASLD in persons with HIV is associated with high cardiometabolic risk as evidenced by altered advanced lipoprotein profiles and targeted metabolomics
Kung-Hung Lin, Eduardo Vilar‐Gómez, Kathleen E. Corey, et al.
Lipids in Health and Disease (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome – current insights and future directions
Bruno Basil, B. Myke-Mbata, Onyinye Ezinne Eze, et al.
Clinical Diabetes and Endocrinology (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 2
Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease
Monica A. Tincopa, Rohit Loomba
Seminars in Liver Disease (2024) Vol. 44, Iss. 03, pp. 287-299
Closed Access | Times Cited: 1
Current Status of Genetics and Polygenic Risk Scores in Metabolic Dysfunction-Associated Steatohepatitis.
Naga Chalasani
PubMed (2024) Vol. 20, Iss. 8, pp. 460-503
Closed Access
PNPLA3 as a driver of steatotic liver disease: navigating from pathobiology to the clinics via epidemiology
Ralf Weiskirchen, Amedeo Lonardo
Journal of Translational Genetics and Genomics (2024) Vol. 8, Iss. 4, pp. 355-77
Open Access
New Diagnostic and Prognostic Models for the Development of Alcoholic Cirrhosis Based on Genetic Predisposition and Alcohol History
Monica Mischitelli, Alessandra Spagnoli, Aurelio Abbatecola, et al.
(2023)
Open Access | Times Cited: 1
New Diagnostic and Prognostic Models for the Development of Alcoholic Cirrhosis Based on Genetic Predisposition and Alcohol History
Monica Mischitelli, Alessandra Spagnoli, Aurelio Abbatecola, et al.
Biomedicines (2023) Vol. 11, Iss. 8, pp. 2132-2132
Open Access
Page 1

Scroll to top